BOSTON (MedPage Today) -- A biologic drug targeting the granulocyte-macrophage colony stimulating factor was safe and showed hints of activity against brain lesions in multiple sclerosis patients in a phase I trial.
BOSTON (MedPage Today) -- An investigational oral drug for multiple sclerosis with the same mechanism as the approved product fingolimod (Gilenya) was highly effective in a phase II trial with seemingly fewer effects on cardiac function than the...
Partners Biogen Idec and AbbVie are touting late-stage results for their new, monthly multiple sclerosis treatment, preparing to hand in regulatory applications next year and contend in a crowded market.
BOSTON (MedPage Today) -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head...
BOSTON (MedPage Today) -- A closely watched phase I trial of autologous mesenchymal stem cells (MSCs) for multiple sclerosis proved that the treatment was safe, with some hints that it might have helped some patients on the efficacy side.
BOSTON (MedPage Today) -- A strong correlation between myelin water fraction and clinical disease measures in multiple sclerosis supports a role for the former in patient management and as an outcome measure in clinical trials.
Today Biogen Idec (NASDAQ: BIIB) announced new data from the second year of
its Phase 3 ADVANCE clinical trial that show the positive treatment effects of
PLEGRIDY™ (peginterferon beta-1a) were maintained in people with relapsing
Today Biogen Idec (NASDAQ: BIIB) announced that five-year results from the
ENDORSE Phase 3 extension study show TECFIDERA^® (dimethyl fumarate) provides
strong and sustained efficacy in a broad range of people living with